A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission after allogenic stem cell transplantation.

Trial Profile

A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission after allogenic stem cell transplantation.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms Sormain
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Oct 2016 This trial has been suspended in Germany.
    • 30 Aug 2011 Additional trial identifiers (DRKS00000591, 4036508) identified, actual initiation date is 29 Oct 2010 and trial investigator identified as reported by German Clinical Trials Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top